Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

Institut de recherches cliniques de Montréal

$713,954.00

Hedgehog signaling and medulloblastoma tumorigenesis

FY 2011-12

Summary
Medulloblastoma is a very aggressive childhood cerebellum cancer and the most common brain tumor in children. One of the important causes of medulloblastoma is aberrant activation of the Sonic hedgehog (Shh) signaling pathway. Our lab recently identified a novel receptor for the secreted protein Shh. Using molecular and genetic approaches, we propose to identify the role of this receptor in medulloblastoma tumorigenesis. Defining the role of this novel Shh receptor in medulloblastoma will improve our knowledge on the molecular events involved in this cancer. Hopefully, this research will facilitate the discovery of more effective therapeutic agents that will help treat or prevent medulloblastoma and possibly other cancers that result from aberrant Shh signaling.
Program
Operating Grant
Location
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
255536
Name
Charron Frederic
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Hedgehog signaling and medulloblastoma tumorigenesis
Programtype2
Operating Grants
Orgnameinp2
Institut de recherches cliniques de Montréal
Cihramount2
$713,954
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Cerebellum; Genetics; Hedgehog; Medulloblastoma; Mouse; Patched1; Signal Transduction
Abstract
Medulloblastoma is a very aggressive childhood cerebellum cancer and the most common brain tumor in children. One of the important causes of medulloblastoma is aberrant activation of the Sonic hedgehog (Shh) signaling pathway. Our lab recently identified a novel receptor for the secreted protein Shh. Using molecular and genetic approaches, we propose to identify the role of this receptor in medulloblastoma tumorigenesis. Defining the role of this novel Shh receptor in medulloblastoma will improve our knowledge on the molecular events involved in this cancer. Hopefully, this research will facilitate the discovery of more effective therapeutic agents that will help treat or prevent medulloblastoma and possibly other cancers that result from aberrant Shh signaling.
Competitiondate
201203
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Charron, Frederic
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $713,954~ $0~